Stevanato Group account plan
glass containers and components
At a glance
Stevanato Group makes drug containers, delivery devices and pharma equipment in Italy: €1,186.3 million FY2025 revenue, 6,010 employees.
Stevanato Group, based in Piombino Dese (Padua) and listed on the NYSE as STVN since July 2021, supplies drug containment (syringes, cartridges, vials), drug delivery devices, diagnostic consumables and pharmaceutical manufacturing equipment. It serves more than 700 companies, including 23 of the top 25 pharmaceutical companies, from 13 manufacturing plants in Italy, Germany, Slovakia, Brazil, Mexico, China, the United States and Denmark. FY2025 revenue was €1,186.3 million, up 7.4% reported and 9.1% at constant currency, with net profit of €139.8 million and Adjusted EBITDA of €298.0 million (25.1% margin); it had 6,010 employees at 31 December 2025. The founding family controls it through Stevanato Holding S.r.l., which holds about 73.73% of share capital and 93.09% of voting rights; Franco Stevanato is Chairman and CEO.
Business units
Biopharmaceutical and Diagnostic Solutions (BDS)
88% of FY2025 revenue (€1,038.2 million)Containers and delivery systems for pharmaceutical and biotech drugs: pre-fillable syringes, cartridges, vials and ampoules (EZ-fill®, Nexa®, Alba®), proprietary devices such as the Alina® and Deora™ pens and the Aidaptus® auto-injector, device contract manufacturing, in-vitro diagnostic consumables and analytical services. Revenue grew 11.2% in 2025, with high-value solutions up 29.4% to €546.4 million; in Q3 2026 BDS external revenue rose 10% to €294.0 million. Biologics were 41% of BDS revenue in 2025, up from 34%.
Engineering
12% of FY2025 revenue (€148.1 million)Machinery built in Piombino Dese, Bologna and Silkeborg (Denmark): assembly and packaging lines for pens, auto-injectors and on-body systems, pharmaceutical visual inspection lines, glass converting lines and after-sales services. Revenue fell 13.0% in 2025 and gross margin dropped to 11.0% from 15.7% on complex legacy projects in Denmark and lower order intake; 2026 Engineering revenue is now expected at €124-134 million.
Strategic priorities
- Shift the mix to high-value solutions
- High-value solutions reached 46.0% of revenue in 2025 (38.3% in 2024) and are guided at 47% to 48% of revenue for 2026, with capacity focused on EZ-fill® and premium syringes.
- Grow in biologics beyond GLP-1s
- The CEO calls biologics' share of BDS "our most important KPI"; non-GLP-1 biologics grew over 30% in Q3 2026, and of more than 9,000 injectable assets in the pipeline, over 60% are biologics.
- Build a drug delivery device business
- Proprietary platforms Alina®, Deora™ and Aidaptus® plus device contract manufacturing; a liraglutide therapy using the Alina® pen was approved in several European countries in 2026, and Alina® capacity in Germany is being expanded.
- Expand in North America
- North America grew 17.2% to €362.1 million in 2025 (30.5% of revenue); the Fishers, Indiana plant is to be fully ramped by end-2028.
- Return Engineering to profitable growth
- A business optimization plan launched in 2024 moves activities from Denmark to Italy and right-sizes the structure; management is assessing the dilutive visual inspection and assembly activities.
- Margin expansion and positive cash flow
- Capital Markets Day targets of 29% to 30% EBITDA margin are reaffirmed as the trajectory, and free cash flow is expected to be positive in 2027.
Latest results
In Q3 2026, revenue rose 8% to €326.1 million (8% organic): BDS external revenue grew 10% to €294.0 million while Engineering fell 12% to €32.0 million. Adjusted EBITDA increased 14% to €88.8 million, a 27.2% margin, and net profit rose 16% to €41.8 million. GLP-1 therapies fell to about 17% to 18% of revenue, while non-GLP-1 biologics grew over 30%. Over nine months revenue was €901.6 million against €839.8 million. Full-year 2026 guidance was maintained at revenue of €1.260-1.280 billion, adjusted EBITDA of €335.0-345.2 million and adjusted diluted EPS of €0.60-0.62; management expects lower GLP-1 volumes in 2027 and low-single-digit growth that year.
Investments and deals
- EZ-fill® capacity in Latina and Fishers
- 2025 capex was €294.9 million, of which €100.8 million in Latina, Italy and €65.6 million in Fishers, Indiana; new RTU 400 cartridge lines in Latina are to generate revenue from 2027.
- Fishers, Indiana plant
- Commercial production since 2024, up to 565,000 sq ft; BARDA committed up to about $95 million for vial capacity. It broke even at gross-profit level in Q3 2026 with about 50% of capacity installed.
- Molding and device assembly
- €66.4 million of 2025 capex went to plastic injection molding and assembly for IVD and devices; contract manufacturing of auto-injectors for a large U.S. client is to start at end-2026 or early 2027.
- Bologna Engineering site
- A new facility near Bologna was acquired in Q4 2025 for Engineering (€5.0 million of 2025 capex).
- Sale of Balda C. Brewer
- The California contract manufacturer of consumables and point-of-care diagnostic parts was sold in Q2 2026, with €12.2 million of one-off costs; 2026 capex is now €230-240 million.
Challenges and risks
- Lower GLP-1 volumes in 2027
- Lower volumes than previously expected, tied to one customer and to Nexa® syringes, are expected to moderate growth to low-single digits in 2027.
- Engineering below expectations
- Order conversion is delayed and Q3 2026 Engineering gross margin was 10.2%; the segment remains dilutive to corporate margin.
- Customer concentration
- The ten largest customers made 53.6% of 2025 revenue and one customer 12%.
- Energy costs and tariffs
- Higher European gas and energy prices weighed on Q3 2026 margins, and U.S. tariffs of 15% apply on goods shipped from Italy.
- Plant ramp-up costs
- Start-up costs for Fishers and Latina were €6.7 million in the first nine months of 2026, and ramp-up inefficiencies are a named risk.
What leadership says
“where there is an injection, Stevanato wants to be in”
“confident in our ability to grow low-single digits next year, based on what we know today.”
“good business, but they remain dilutive to our corporate margin”
“8 years to develop and launch on the market this Alina® product”
Where a supplier can help
- Plant ramp-up and automation
- Tied to the Latina and Fishers investments and their ramp-up costs: suppliers of cleanroom, validation, automation and maintenance services can help bring lines to full output by end-2028.
- Energy management
- Tied to the energy-cost challenge: European gas and energy prices hit Q3 2026 margins, so energy procurement and efficiency offers fit the plants in Italy and Germany.
- Device contract manufacturing inputs
- Tied to the drug delivery device priority: scale-up of Alina® and contract manufacturing in Germany and Fishers needs molding, components and assembly partners.
- Engineering order conversion
- Tied to the Engineering challenge: tools that shorten long technical sales cycles and project execution could support the optimization plan.
- Biologics customer acquisition
- Tied to the biologics priority and customer concentration: sales intelligence on biotech and biosimilar programs can widen a base where ten customers make 53.6% of revenue.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Stevanato Group?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 20-F for the fiscal year ended December 31, 2025
- Stevanato Group (Piombino Dese, Padua; NYSE: STVN since July 2021) is a global provider of drug containment, drug delivery and diagnostic solutions plus pharmaceutical manufacturing equipment, serving more than 700 companies including 23 of the top 25 pharmaceutical companies.
- FY2025 revenue was €1,186.3 million, up 7.4% reported and 9.1% at constant currency; net profit €139.8 million (+18.7%), diluted EPS €0.51 (adjusted €0.54); Adjusted EBITDA €298.0 million, a 25.1% margin.
- Two segments: Biopharmaceutical and Diagnostic Solutions (BDS) made 88% of revenue (€1,038.2 million, +11.2%) and Engineering 12% (€148.1 million, -13.0%).
- High-value solutions (EZ-fill®, Nexa®, Alba®, proprietary devices) rose 29.4% to €546.4 million and reached 46.0% of revenue, against 38.3% in 2024; GLP-1s were an estimated 19% to 20% of revenue.
- Capex was €294.9 million, mostly EZ-fill® capacity in Latina, Italy (€100.8 million) and Fishers, Indiana (€65.6 million); free cash flow turned positive at €18.4 million (from -€148.5 million); net debt €337.7 million.
- Engineering is the weak spot: gross margin fell to 11.0% from 15.7% on complex legacy projects in Denmark and lower new order intake, despite a business optimization plan.
- North America grew 17.2% to €362.1 million (30.5% of revenue); EMEA remains the largest region at €690.3 million (58.2%).
- Concentration: the ten largest customers made 53.6% of revenue and one customer 12%; backlog was about €871 million at year end.
- Founding family control: Stevanato Holding S.r.l. holds about 73.73% of share capital and 93.09% of voting rights; Franco Stevanato is Chairman and CEO, Marco Dal Lago CFO.
- Third Quarter 2026 Results press release (Form 6-K, Exhibit 99.1)
- Q3 2026 revenue rose 8% to €326.1 million, also 8% organically; BDS external revenue €294.0 million (+10%, +11% organic) offset a 12% fall in Engineering to €32.0 million.
- High-value solutions grew 1% to €149.4 million, 46% of total revenue and 51% of BDS revenue, led by EZ-fill® syringes and cartridges; other containment and delivery solutions grew 22% to €144.6 million, helped by variable compensation tied to lower GLP-1 volumes.
- GLP-1 therapies were about 17% to 18% of Q3 revenue; non-GLP-1 biologics grew over 30% in the quarter.
- Adjusted EBITDA rose 14% to €88.8 million, margin 27.2% (+150 bp); net profit €41.8 million (+16%), diluted EPS €0.15, adjusted diluted EPS €0.16.
- Gross margin slipped 10 bp to 29.1% on utility costs, depreciation and weaker Engineering; Fishers and Latina improved.
- Full-year 2026 guidance maintained: revenue €1.260-1.280 billion, adjusted EBITDA €335.0-345.2 million, adjusted diluted EPS €0.60-0.62.
- CEO Franco Stevanato now expects lower GLP-1 volumes in 2027 and growth of low-single digits next year, having already backfilled part of the gap.
- Net debt €353.7 million at 30 September 2026; Q3 capex €44.8 million; Q3 free cash flow €21.7 million.
- Third Quarter 2026 Financial Results Conference Call transcript
- Q3 2026 call (3 Nov 2026) with Chairman and CEO Franco Stevanato and CFO Marco Dal Lago: revenue +8% to €326.1 million, adjusted EBITDA margin 27.2%, full-year 2026 guidance reiterated.
- The main news: lower GLP-1 volumes than expected in 2027, tied to one customer and to Nexa® syringes; the company still expects low-single-digit growth in 2027 and a return to normalized growth in 2028.
- Without that headwind, management says 2027 would have grown in line with the long-range plan of high-single to low-double-digit growth; the Capital Markets Day targets of 29% to 30% EBITDA margin are reaffirmed as the trajectory.
- Non-GLP-1 biologics grew over 30% in Q3 and 13% year to date; the group works with over 30 GLP-1 customers on more than 50 programs, and patient penetration is below 10%.
- Ready-to-use (RTU) cartridges are fully booked for most of 2027; the first high-volume Alba® syringe line was qualified in Piombino Dese.
- Fishers broke even at gross-profit level in Q3, shipped its first commercial EZ-fill® vial order and is planned to be fully ramped by end-2028; device contract manufacturing starts commercial volumes shortly.
- Engineering is below expectations: order conversion delayed, partly by the same large customer; 2026 Engineering revenue now €124-134 million; the CEO says visual inspection and assembly "remain dilutive" and are under internal assessment.
- 2026 capex now €230-240 million (€215-225 million net of customer contributions); European gas and energy prices weighed on Q3 margins.
- Second Quarter 2026 Financial Results Conference Call transcript
- Q2 2026 call (4 Aug 2026), Chairman and CEO Franco Stevanato and CFO Marco Dal Lago: revenue +8% to €302 million; high-value solutions +16% to €135.9 million (45% of revenue); adjusted EBITDA +21% to €78.7 million, margin 26%.
- Completed the sale of Balda C. Brewer (California contract manufacturer of consumables and point-of-care diagnostic parts, about €30 million expected 2026 revenue), with €12.2 million of one-off costs; it is called margin accretive.
- A customer's liraglutide therapy using the proprietary Alina® pen was approved in several European countries, for diabetes and weight management; the CEO calls it "maybe one of our most big milestone in 2026" after 8 years of development.
- The fixed-dose Deora™ pen was introduced; Alina® is expected to generate double-digit revenue growth in coming years, produced in Germany.
- Biologics are now more than 42% of BDS revenue, against a little less than 20% in 2022; GLP-1s were about 22% to 23% of Q2 revenue.
- 2026 guidance: revenue €1.260-1.280 billion, adjusted EBITDA €335-345.2 million, adjusted EPS €0.60-0.62, free cash flow from breakeven to €20 million; tax rate about 28.2%.
- Engineering margins improved strongly (gross margin 12%, +540 bp), but sales cycles are longer; Fishers is to be fully ramped by end-2028.
- More than €1.3 billion has been invested since the 2021 IPO, mostly in high-value products; non-core bulk lines (ampoules, standard diagnostic plastics) are being gradually deprioritised.
- Fourth Quarter and Full Year 2025 Financial Results Conference Call transcript
- FY2025 and Q4 call (4 Mar 2026), Chairman and CEO Franco Stevanato and CFO Marco Dal Lago: 2025 revenue +9% at constant currency (+7% reported); high-value solutions +29% to 46% of revenue; gross margin +160 bp.
- GLP-1s were about 19% to 20% of 2025 revenue, growing more than 50%; mid-teens GLP-1 growth is expected in 2026. Nexa® syringes were the fastest-growing product.
- Biologics rose to 41% of BDS revenue from 34% in 2024; customers ordering premium syringes (Alba®, Nexa®) for non-GLP-1 biologics increased 40%.
- 2026 guidance: revenue €1.260-1.290 billion, adjusted EBITDA €331.8-346.9 million, adjusted diluted EPS €0.59-0.63; capex €270-290 million gross; free cash flow from breakeven to about €20 million.
- Q4 2025: revenue €346.5 million (+5% reported), high-value solutions +31% to €171 million (about 49% of revenue), adjusted EBITDA margin 28.2%.
- Engineering: optimization is working operationally (site acceptance tests up double digits), but order conversion is slower; 2026 revenue is expected to decline.
- Fishers: the number of validated customers doubled in 2025, and contract manufacturing of auto-injectors for a large U.S. client should start at end-2026 or early 2027.
- The CEO expects injectables to keep about 70% of the GLP-1 market against about 30% for orals.
Questions about Stevanato Group
What does Stevanato Group do?
It makes pharmaceutical-grade glass drug containers such as pre-fillable syringes, cartridges and vials, drug delivery devices, diagnostic consumables and the machinery used to make and inspect them, for pharmaceutical, biotech and diagnostic companies.
What is Stevanato Group's revenue?
FY2025 revenue was €1,186.3 million, up 7.4% reported, and 2026 guidance is €1.260-1.280 billion.
How many employees does Stevanato Group have?
It had 6,010 employees at 31 December 2025, about 58% of them in Italy.
What is Stevanato Group's strategy?
Grow high-value solutions such as EZ-fill®, Nexa® and Alba®, expand in biologics and drug delivery devices, build capacity in Latina and Fishers, and restore Engineering's profitability.
Who leads Stevanato Group?
Franco Stevanato is Chairman and CEO and Marco Dal Lago is CFO; the family holding company holds 93.09% of voting rights.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)